Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alex Detwiler

Orthopaedic Surgery of the Spine Stillwater, OK Doctor of Osteopathy

NPI 1831519107 CMS profile 5701702

1301 W 6Th Ave Ste 207, Stillwater, OK 74074

Open in the dashboard

General payments

$12,923

105 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alex Detwiler of Stillwater, OK is reported in the CMS Open Payments database as having received $12,923 across 105 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 50th percentile of Orthopaedic Surgery of the Spine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,834 17
2024 General $1,377 11
2023 General $2,639 14
2022 General $855 10
2021 General $2,152 25
2020 General $1,696 22
2019 General $1,370 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alex Detwiler
  • Orthopaedic Surgery of the Spine median
  • Middle half of Orthopaedic Surgery of the Spine
  • National median

In program year 2025, general payments to Alex Detwiler were reported at $2,834. Among 1,704 Orthopaedic Surgery of the Spine profiles paid that year, the median was $2,061 and the middle half received between $347 and $14,651.

Show as a table
Year Alex Detwiler Orthopaedic Surgery of the Spine median Middle half National median
2019 $1,370 $2,106 $337–$18,608 $163
2020 $1,696 $1,213 $156–$15,082 $114
2021 $2,152 $1,834 $271–$15,617 $132
2022 $855 $2,015 $320–$17,036 $149
2023 $2,639 $1,925 $336–$14,599 $160
2024 $1,377 $2,110 $341–$12,483 $164
2025 $2,834 $2,061 $347–$14,651 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $3,318 32 payments
  2. Alphatec Spine, Inc $2,955 11 payments
  3. Providence Medical Technology, Inc. $2,695 12 payments
  4. Pylant Medical $1,044 1 payment
  5. SI-BONE, Inc. $822 11 payments
  6. Medtronic USA, Inc. $701 13 payments
  7. Centinel Spine, LLC $501 5 payments
  8. Relievant Medsystems, Inc. $306 5 payments
  9. Orthofix Medical, Inc. $152 2 payments
  10. Boston Scientific Corporation $106 4 payments
  11. Other $323 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $6,997 26 payments
  2. Food and Beverage $4,882 78 payments
  3. Education $1,044 1 payment
Products named General payments · program years 2019–2025
  1. Other - Miscellaneous $2,530 5 payments
  2. EVEREST SPINAL SYSTEM $1,669 15 payments
  3. SERRATO $708 5 payments
  4. MESA $708 5 payments
  5. VLIFT $708 5 payments
  6. CAPRI $708 5 payments
  7. YUKON $708 5 payments
  8. N/A $491 4 payments
  9. PRODISC L $329 4 payments
  10. Intracept $306 5 payments
  11. Other $2,673 49 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

458

Median for Orthopedic Surgery: 203

Drug cost

$3,997

Median for Orthopedic Surgery: $1,433

Branded share of claims

25.5%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 223 $2,190
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 117 $1,160
Methocarbamol Generic 56 $260
Methylprednisolone Generic 28 $195
Duloxetine Hcl Generic 20 $111
Meloxicam Generic 14 $81

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$198,223

Medicare's payments for the services billed

Medicare patients

614

Average age 74

Services billed

2,144

376 women, 238 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 34%
Ischemic heart disease 33%
Depression 31%
Osteoporosis 20%
Heart failure 19%
COPD 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

105 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery of the Spine in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record